Qualigen Therapeutics (QLGN) Competitors $3.80 +0.02 (+0.53%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$3.30 -0.50 (-13.03%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. INDP, ACXP, NEUP, TSBX, SLXN, MYNZ, RLMD, ABVC, PHIO, and CHROShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Indaptus Therapeutics (INDP), Acurx Pharmaceuticals (ACXP), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Turnstone Biologics (TSBX), Silexion Therapeutics (SLXN), Mainz Biomed (MYNZ), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Phio Pharmaceuticals (PHIO), and Chromocell Therapeutics (CHRO). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Indaptus Therapeutics Acurx Pharmaceuticals Neuphoria Therapeutics Inc. - Common Stock Turnstone Biologics Silexion Therapeutics Mainz Biomed Relmada Therapeutics ABVC BioPharma Phio Pharmaceuticals Chromocell Therapeutics Qualigen Therapeutics (NASDAQ:QLGN) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking. Do insiders and institutionals believe in QLGN or INDP? 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in QLGN or INDP? Indaptus Therapeutics received 6 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 86.67% of users gave Indaptus Therapeutics an outperform vote. CompanyUnderperformOutperformQualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50%Indaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Does the media favor QLGN or INDP? In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 2 articles in the media. Indaptus Therapeutics' average media sentiment score of 0.94 beat Qualigen Therapeutics' score of 0.93 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend QLGN or INDP? Indaptus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 1,340.68%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Indaptus Therapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is QLGN or INDP more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A -424.18% Indaptus Therapeutics N/A -177.27%-141.06% Which has more risk & volatility, QLGN or INDP? Qualigen Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Which has higher valuation and earnings, QLGN or INDP? Qualigen Therapeutics has higher revenue and earnings than Indaptus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen Therapeutics$4.98M0.56-$13.42MN/AN/AIndaptus TherapeuticsN/AN/A-$15.42M-$1.62-0.36 SummaryIndaptus Therapeutics beats Qualigen Therapeutics on 9 of the 13 factors compared between the two stocks. Remove Ads Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E RatioN/A7.2623.6018.74Price / Sales0.56218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book-0.196.386.894.23Net Income-$13.42M$142.34M$3.20B$247.47M7 Day Performance18.01%-5.15%-3.06%-2.29%1 Month Performance19.87%-7.55%1.52%-5.81%1 Year Performance-81.00%-11.06%9.37%-0.96% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.80+0.5%N/A-81.0%$2.80M$4.98M0.0050Upcoming EarningsGap UpHigh Trading VolumeINDPIndaptus Therapeutics3.7518 of 5 stars$0.66-8.4%$8.50+1,187.9%-73.7%$9.52MN/A-0.396High Trading VolumeACXPAcurx Pharmaceuticals3.1333 of 5 stars$0.43+1.8%$12.00+2,684.9%-83.3%$9.50MN/A-0.403NEUPNeuphoria Therapeutics Inc. - Common Stock1.9427 of 5 stars$5.40+0.4%$21.00+288.9%N/A$9.49M$662,715.000.00N/AGap UpTSBXTurnstone Biologics1.0494 of 5 stars$0.41-0.2%$0.45+10.0%-84.3%$9.46M$19.31M-0.1382News CoverageGap DownSLXNSilexion TherapeuticsN/A$1.12-1.8%$5.00+346.4%N/A$9.43MN/A0.00N/ANews CoverageGap UpMYNZMainz Biomed2.2016 of 5 stars$4.62+0.9%$14.00+203.0%-91.3%$9.25M$917,203.00-0.0730Short Interest ↑News CoverageGap UpRLMDRelmada Therapeutics3.8764 of 5 stars$0.30+1.9%$4.25+1,307.3%-93.6%$9.11MN/A-0.1110Earnings ReportUpcoming EarningsNews CoverageGap UpABVCABVC BioPharma1.3808 of 5 stars$0.70+1.2%N/A-34.4%$9.06M$509,788.00-0.8130Upcoming EarningsShort Interest ↓Positive NewsPHIOPhio Pharmaceuticals2.9127 of 5 stars$1.30+0.8%$4.00+207.7%-78.9%$8.95MN/A-0.1210Gap UpCHROChromocell TherapeuticsN/A$1.48-5.7%N/A-39.3%$8.92MN/A0.004Gap Down Remove Ads Related Companies and Tools Related Companies INDP Competitors ACXP Competitors NEUP Competitors TSBX Competitors SLXN Competitors MYNZ Competitors RLMD Competitors ABVC Competitors PHIO Competitors CHRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QLGN Stock Free QLGN Stock Alerts